glp 1 approved for Novo's Wegovy becomes first GLP-1 drug MASH How Employers Can Optimize Benefits
Description
It's going to slow down your GI tract
Bergenstal RM, Li Y, Porter TKB, Weaver C, Han J
Note that a 503A pharmacy won't appear on the FDAs 503B list - that's expected, as 503A pharmacies aren't required to register with the FDA
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that primarily works by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite
Archivos de investigacion medica [Internet]
